LIT-001

Research use only, not for human use.

LIT-001 improves social interaction in a mouse model of autism.It is the first nonpeptide oxytocin receptor agonist with EC50 of 55 nM and Ki of 226 nM.

LIT-001 improves social interaction in a mouse model of autism.It is the first nonpeptide oxytocin receptor agonist with EC50 of 55 nM and Ki of 226 nM.In the in vitro signal transduction experiment, LITL-001 is an unbiased OT-R agonist, acting on the two main signal transduction pathways of this receptor, with slight antagonistic effect on V1a and agonist effect on V1b receptor, only observed at high concentration.LIT-001 (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD).

In vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with minor antagonist effect on V1a and agonist effect on V1b receptors, observed at high concentrations only.

LIT-001 (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD ). Animal Model:Oprm1–/– mice (bred in house on a 50% 129SVPas–50% C57BL/6J hybrid background) Dosage:10, 20 mg/kg Administration:i.p.Result:Alleviated core symptoms in the context of ASD.

——

Others

Other Targets

oxytocin receptor

——

——

2245072-21-1

645.7

C30H34F3N7O4S

>98% (HPLC)

DMSO:247 mg/mL (382.53mM; Need ultrasonic)

OC(=O)C(F)(F)F.CN(C)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12

——

(-20℃)

With Ice Pack

≥ 2 years